

## University of Groningen

### Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation

Dwyer, Daniel F; Ordovas-Montanes, Jose; Allon, Samuel J; Buchheit, Kathleen M; Vukovic, Marko; Derakhshan, Tahereh; Feng, Chunli; Lai, Juying; Hughes, Travis K; Nyquist, Sarah K

*Published in:*  
 Science immunology

*DOI:*  
[10.1126/sciimmunol.abb7221](https://doi.org/10.1126/sciimmunol.abb7221)

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*  
 Final author's version (accepted by publisher, after peer review)

*Publication date:*  
 2021

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Dwyer, D. F., Ordovas-Montanes, J., Allon, S. J., Buchheit, K. M., Vukovic, M., Derakhshan, T., Feng, C., Lai, J., Hughes, T. K., Nyquist, S. K., Giannetti, M. P., Berger, B., Bhattacharyya, N., Roditi, R. E., Katz, H. R., Nawijn, M. C., Berg, M., van den Berge, M., Laidlaw, T. M., ... Boyce, J. A. (2021). Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation. *Science immunology*, 6(56), Article 7221. <https://doi.org/10.1126/sciimmunol.abb7221>

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*



Published in final edited form as:

*Sci Immunol.* 2021 February 26; 6(56): . doi:10.1126/sciimmunol.abb7221.

## Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation: Single-cell RNA sequencing characterization of mast cell hyperplasia in nasal polyposis

Daniel F. Dwyer<sup>#1,2</sup>, Jose Ordovas-Montanes<sup>#3,4,5,6</sup>, Samuel J. Allon<sup>5,7,8</sup>, Kathleen M. Buchheit<sup>1,2</sup>, Marko Vukovic<sup>5,7,8</sup>, Tahereh Derakhshan<sup>1,2</sup>, Chunli Feng<sup>1,2</sup>, Juying Lai<sup>1,2</sup>, Travis K. Hughes<sup>5,7,8</sup>, Sarah K. Nyquist<sup>5,7,8,9</sup>, Matthew P. Giannetti<sup>1,2</sup>, Bonnie Berger<sup>10</sup>, Neil Bhattacharyya<sup>2,11</sup>, Rachel E. Roditi<sup>2,11</sup>, Howard R. Katz<sup>1,2</sup>, Martijn C. Nawijn<sup>12,13</sup>, Marijn Berg<sup>12,13</sup>, Maarten van den Berge<sup>12,14</sup>, Tanya M. Laidlaw<sup>1,2</sup>, Alex K. Shalek<sup>#5,7,8</sup>, Nora A. Barrett<sup>#1,2,4</sup>, Joshua A. Boyce<sup>#1,2,4,+</sup>

<sup>1</sup>Jeff and Penny Vinik Immunology Center, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA, USA <sup>2</sup>Department of Medicine, Harvard Medical School, Boston, MA, USA <sup>3</sup>Division of Gastroenterology, Boston Children's Hospital, Boston, MA, USA <sup>4</sup>Program in Immunology, Harvard Medical School, Boston, MA, USA <sup>5</sup>Broad Institute of MIT and Harvard, Cambridge, MA, USA <sup>6</sup>Harvard Stem Cell Institute, Cambridge, MA, USA <sup>7</sup>Institute for Medical Engineering and Science (IMES), Department of Chemistry, and Koch Institute for Integrative Cancer Research, MIT, Cambridge, MA, USA <sup>8</sup>Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA <sup>9</sup>Program in Computational and Systems Biology, MIT, Cambridge, MA, USA <sup>10</sup>Computer Science and Artificial Intelligence Lab and Department of Mathematics, MIT, Cambridge, MA, USA <sup>11</sup>Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA <sup>12</sup>University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands <sup>13</sup>University of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, laboratory of experimental immunology and respiratory research (EXPIRE), Groningen, the Netherlands <sup>14</sup>University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, the Netherlands

<sup>+</sup>Denotes lead contact

### Author Contributions

J.O.M., D.F.D., S.J.A., T.M.L., A.K.S., N.A.B., and J.A.B. designed the study. N.B. and R.E.R. performed surgeries. J.O.M., D.F.D., S.J.A., M.V., T.K.H., K.M.B., and M.P.G., collected patient samples and performed single-cell experiments. D.F.D., T.D., and M.P.G. conducted validation studies. C.F. conducted in vitro CBMC stimulus experiments. H.R.K. and J.L. performed histologic analyses. M.C.N., M.B., and M.v.d.B. conducted scRNA-seq analysis of asthma-derived MCs. D.F.D., J.O.M., S.J.A., and S.K.N. analyzed data. J.O.M., D.F.D., S.J.A., A.K.S., N.A.B., and J.A.B. interpreted data. J.O.M., D.F.D., S.J.A., A.K.S., N.A.B., and J.A.B. wrote the manuscript, with input from all authors.

### Competing interests

J.O.M. reports compensation for consulting services with Cellarity and Hovione. R.E.R. reports compensation for consulting services with Roche Genentech and Gossamer pharmaceuticals. N.A.B. reports compensation for consulting services for Regeneron. A.K.S. reports compensation for consulting and/or SAB membership from Merck, Honeycomb Biotechnologies, Cellarity, Repertoire Immune Medicines, Ocrhe Bio, Hovione, and Dahlia Biosciences.

### Data and materials availability:

A cell x gene matrix generated from sorted nasal polyp-derived mast cell and analyzed during the current study is available along with the manuscript as Supplementary Table 3. Single-cell RNA sequencing raw data in FASTQ format have been deposited in dbGaP under accession no. phs002333.v1.p1. Bulk sequencing data have been deposited in the Gene Expression Omnibus under accession no. GSE165804.

# These authors contributed equally to this work.

## Abstract

Mast cells (MCs) play a pathobiologic role in type 2 (T2) allergic inflammatory diseases of the airway, including asthma and chronic rhinosinusitis with nasal polyposis (CRSwNP). Distinct MC subsets infiltrate the airway mucosa in T2 disease, including subepithelial MCs expressing the proteases tryptase and chymase (MC<sub>TC</sub>) and epithelial MCs expressing tryptase without chymase (MC<sub>T</sub>). However, mechanisms underlying MC expansion and the transcriptional programs underlying their heterogeneity are poorly understood. Here we use flow cytometry and single-cell RNA-sequencing (scRNA-seq) to conduct a comprehensive analysis of human MC hyperplasia in CRSwNP, a T2 cytokine-mediated inflammatory disease. We link discrete cell surface phenotypes to the distinct transcriptomes of CRSwNP MC<sub>T</sub> and MC<sub>TC</sub>, which represent polarized ends of a transcriptional gradient of nasal polyp MCs. We discover a subepithelial population of CD38<sup>high</sup>CD117<sup>high</sup> MCs that is markedly expanded during T2 inflammation. These CD38<sup>high</sup>CD117<sup>high</sup> MCs exhibit an intermediate phenotype relative to the expanded MC<sub>T</sub> and MC<sub>TC</sub> subsets. CD38<sup>high</sup>CD117<sup>high</sup> MCs are distinct from circulating MC progenitors and are enriched for proliferation, which is markedly increased in CRSwNP patients with aspirin-exacerbated respiratory disease (AERD), a severe disease subset characterized by increased MC burden and elevated MC activation. We observe that MCs expressing a polyp MC<sub>T</sub>-like effector program are also found within the lung during fibrotic diseases and asthma, and further identify marked differences between MC<sub>TC</sub> in nasal polyps and skin. These results indicate that MCs display distinct inflammation-associated effector programs and suggest *in situ* MC proliferation is a major component of MC hyperplasia in human T2 inflammation.

## Keywords

Mast cell; type 2 inflammation; human immunology; nasal polyposis; scRNA-seq

## Introduction

Mast cells (MCs) are found in all barrier tissue sites under homeostatic conditions, where they are critical for host defense against helminths, viruses, bacteria, and xenobiotic venoms (1). MC expansion occurs across a spectrum of diseases associated with type 2 (T2) inflammation, including asthma, food allergy, eosinophilic esophagitis (EoE), and atopic dermatitis. MCs participate in T2 inflammatory disease progression and severity through eicosanoid biosynthesis, cytokine production, and the release of pre-formed mediators, including histamine and proteases (1–3). Pharmacologic inhibition of the MC survival receptor CD117 using imatinib reduces airway hyperresponsiveness in subjects with refractory asthma but only modestly decreases lung MC burden (2). Thus, developing a better mechanistic understanding of MC hyperplasia in human diseases may enable more directed and effective approaches for targeting MC-dependent pathobiology.

Two major human MC subtypes distinguished by tissue microlocalization and histologically-defined protease expression patterns have been recognized within barrier tissues. Subepithelial MCs co-express the proteases tryptase and chymase (MC<sub>TC</sub>) in conjunction

with cathepsin G and carboxypeptidase A3 (CPA3). Mucosal epithelial MCs express tryptase but lack chymase, cathepsin G and CPA3 (MC<sub>T</sub>) (4, 5). Rodent studies demonstrate that subepithelial compartments are seeded by fetal-derived  $\beta$ 7 integrin (Itg $\beta$ 7)-expressing MC progenitors (MC<sub>P</sub>) that maintain the MC populations in these locations through adulthood (6, 7). In contrast, mucosal epithelial MCs arise from adult bone marrow-derived Itg $\beta$ 7-expressing MC<sub>P</sub> (8–10). Both the fetal- and adult bone marrow-derived murine MC compartments are strongly influenced by local microenvironments, with fetal-derived MCs expressing tissue-specific transcriptional programs (11) and both MC classes exhibiting tissue-dependent protease expression profiles (12). While a committed human MC<sub>P</sub> expressing CD34 and Itg $\beta$ 7 exists in adult peripheral blood (13) and fetal cord blood (14), how mature human tissue MCs are maintained and the degree to which human MCs exhibit tissue-specific phenotypes are unknown.

T2 inflammatory airway disease markedly changes the number, distribution, phenotype, and likely the functional characteristics of MCs. Mild to moderate asthma, EoE, and chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) all involve expansion of an intraepithelial MC<sub>T</sub> population expressing CPA3, suggesting a common paradigm underlying human mucosal T2 inflammation and a broader “Inflammatory MC<sub>T</sub>” effector program (15–18). In asthma, the concentrations of these inflammatory MC<sub>T</sub> correlate with epithelial T2-induced gene signatures and therapeutic responses to inhaled glucocorticoids, while in EoE these inflammatory MC<sub>T</sub> exhibit degranulation during active disease (15, 18). The airway smooth muscle of severe asthmatics is additionally infiltrated by MC<sub>TC</sub>, where their concentration correlates with disease severity and airway hyper-responsiveness (16, 19, 20). MC<sub>TC</sub> also expand in subepithelial glandular tissue in CRSwNP (17). Although the differential effector programs of these MC phenotypes are largely unknown, MCs harvested from polyp epithelium have decreased sensitivity to IgE-mediated activation relative to those from the subepithelium (21), indicating broader functional differences accompanying protease phenotypes. Although the expanded nasal polyp MC pool likely shares key features with that observed across human mucosal T2 inflammation, the determinants of this MC expansion and phenotypic alterations remain largely unknown.

We recently used single-cell RNA-sequencing (scRNA-seq) to deconstruct inflammatory circuits across epithelial, stromal, and immune cells in nasal polyposis, identifying MCs as a source of both T2 inflammatory cytokines (*IL5*, *IL13*), and lipid mediator biosynthetic enzymes (*ALOX5*, *ALOX5AP*, *HPGDS*) (22). Here, we utilize directed scRNA-seq, CITE-seq, and flow cytometry to comprehensively characterize human MC phenotypes and hyperplasia within sinonasal tissues from CRS patients with differing degrees of disease severity. Through this approach, we identify distinct cell surface phenotypes and respiratory inflammation-linked transcript expression patterns associated with a nasal polyp intraepithelial MC<sub>T</sub> program also found in inflamed lung and subepithelial MC<sub>TC</sub>s highly distinct from those found in the skin.

Our scRNA-seq results further suggest that these divergent polyp MC<sub>T</sub> (CD38<sup>high</sup>CD117<sup>low</sup>) and MC<sub>TC</sub> (CD38<sup>low</sup>CD117<sup>high</sup>) phenotypes represent two polarized states along a gradient of MC transcript and protein expression, linked by a CD38<sup>high</sup>CD117<sup>high</sup> intermediate MC. These CD38<sup>high</sup>CD117<sup>high</sup> MCs, present at low concentration in control tissue from

CRS patients without nasal polyps (CRSsNP), are substantially expanded in CRSwNP tissue. This expansion is associated with local proliferation, a process that is significantly increased in tissue from patients with aspirin-exacerbated respiratory disease (AERD), a severe CRSwNP disease variant associated with asthma, rapid nasal polyp growth and high concentrations of MC activation products in biological fluids (23). Thus, our findings identify T2I-associated MC<sub>T</sub> and MC<sub>TC</sub> phenotypes, characterize an intermediate tissue-resident CD38<sup>high</sup> CD117<sup>high</sup> MC transcriptionally linked to both archetypal MC subsets present in polyposis, and suggest MC hyperplasia found in this T2 disease arises in part from local MC proliferation.

## Results

### Characterization of the expanded MC population in T2 inflammation.

Consistent with prior studies (24), flow cytometric analysis demonstrated a prominent population of CD45<sup>+</sup>lin(CD3, CD19, CD11b CD11c)<sup>-</sup>FcεR1α<sup>+</sup>CD117<sup>+</sup> MCs in human nasal polyps that was expanded relative to control tissue from patients with CRSsNP (Fig. 1A). Because patients with nasal polyposis included both aspirin-tolerant subjects and patients with AERD, we further assessed MC concentration between these clinical phenotypes. We noted a significant increase in MC concentration as both percentage of CD45<sup>+</sup> and percentage of all live cells in AERD versus CRSwNP and in both polyp populations relative to CRSsNP (Fig. 1B). Thus, MC expansion occurred proportionately to disease severity.

Nasal polyp MCs exhibited more heterogeneous CD117 expression and side angle light scatter (SSC) than CRSsNP MCs (Fig. 1C), suggesting the presence of one or more additional MC subsets in CRSwNP. Upon fractionating superficial epithelium to analyze intraepithelial MCs, we noted these MCs were CD117<sup>low</sup>SSC<sup>low</sup>, in contrast to unfractionated polyp (Fig. 1D). Based on this observation, we created a flow cytometric gating scheme to distinguish CD117<sup>low</sup>SSC<sup>low</sup> MCs from CD117<sup>high</sup> MCs (Fig. 1E) and confirmed a highly significant epithelial enrichment for CD117<sup>low</sup>SSC<sup>low</sup> MCs, indicating that CD117<sup>high</sup> MCs were predominantly subepithelial (Fig. 1F). Epithelial MCs expressed significantly lower FcεR1α than subepithelial MCs (Fig. 1G) and lacked both CCR3 and HLA-DRA despite detection of both proteins in CD45<sup>+</sup> CD117<sup>-</sup> cells, indicating no basophils or dendritic cell (DC) contamination (Fig. S1C–F). Additionally, no clear population expressing the stem cell lineage marker CD34 was detected within the polyp MC pool (Fig. S1G).

We next sorted CD117<sup>low</sup> SSC<sup>low</sup> epithelial and CD117<sup>high</sup> subepithelial MCs for microscopy characterization. MCs within the epithelial-enriched gate contained metachromatic granules (Fig. 1H, left) and expressed tryptase with a granular staining pattern (Fig. 1H, right, channel series shown in Fig. S2A), indicating a mature MC<sub>T</sub> phenotype. MCs within the subepithelial gate contained a mix of large cells with dense metachromatic granules and smaller less granulated cells with an immature morphology (Fig. 1I, left), suggesting that the range of SSC observed within this gate reflected granular heterogeneity (Fig. 1G). Protease immunostaining indicated that the subepithelial MC pool contained cells co-expressing tryptase and chymase, indicating a MC<sub>TC</sub> phenotype, as well

as MCs exhibiting diffuse tryptase staining without chymase (Fig. 1I, right, channel series shown in Fig. S2B). Consistent with previous studies(17), immunohistologic assessment confirmed that chymase expressing cells were largely restricted to polyp subepithelium (Fig. S2C–D). Thus, MCs within the epithelial gate were MC<sub>T</sub> characterized by reduced FcεR1α and CD117 expression, while subepithelial polyp MCs, exhibiting increased FcεR1α and CD117, were a mix of MC<sub>TC</sub> and morphologically immature MCs.

Given the presence of immature-appearing MCs, we next assessed whether Itgβ7<sup>+</sup>CD34<sup>+</sup> human MC<sub>P</sub>s might participate in polyp MC hyperplasia (13). A subset of SSC<sup>low</sup> MCs expressing Itgβ7 (Itgβ7<sup>high</sup>) was observed within both the epithelial and subepithelial gates (Fig. 2A). Polyp Itgβ7<sup>high</sup> MCs exhibited diffuse tryptase staining and, in contrast to the previously described circulating MC<sub>P</sub>, contained distinct metachromatic granules (Fig. 2B). Itgβ7<sup>high</sup> MCs were virtually absent in CRSsNP tissue (Fig. 2C) and present in similar concentrations in CRSwNP and AERD relative to total MCs (Fig. 2D). Unlike circulating MC<sub>P</sub>, Itgβ7<sup>high</sup> MCs were CD34<sup>-</sup> (Fig. 2E). Itgβ7 pairs with the integrins αE and α4, forming either αEβ7, recognizing the epithelial adhesion molecule E-cadherin, or α4β7, recognizing VCAM and MadCAM (25, 26). While circulating Itgβ7<sup>high</sup> MC<sub>P</sub> expressed only α4, a substantial subset of polyp Itgβ7<sup>high</sup> MCs co-expressed αE (Fig. 2F). These αE<sup>high</sup> MCs were mostly in the epithelial-enriched CD117<sup>low</sup> gate, whereas Itgβ7<sup>high</sup> cells lacking αE were not significantly enriched in either compartment (Fig. 2G). Thus, Itgβ7<sup>high</sup> polyp MCs are a heterogeneous population distinguished from circulating MC<sub>P</sub> by lack of CD34 expression, increased granulation, and expression of αE integrin, together likely reflecting maturation in response to the tissue microenvironment. As αEβ7 binds epithelial-associated E-cadherin (25), its expression could promote accumulation or retention in the epithelial compartment.

### scRNA-seq identification of MC polarization and proliferation.

To further explore polyp MC heterogeneity, we conducted scRNA-seq using the Seq-Well platform on MCs flow sorted from 6 polyp donors (27) (Fig. 3A). We derived a unified cell-by-gene matrix for all cells passing quality control thresholds (n=7,355 cells) and identified 10 cell clusters following dimensionality reduction and unsupervised clustering (Fig. S3A, methods). Contaminating populations were identified by comparison to a series of cell identity transcriptional signatures developed in our prior scRNA-seq study of nasal polyposis (22), including small populations of fibroblasts and epithelial cells, DCs, B/plasma cells, and a population of plasmacytoid DCs (pDC) not resolved in our previous study (Fig. S3B–E, Supplementary Table 2–3). All clusters were observed in CRSwNP and AERD and in all patients aside from one lacking pDCs (Fig. S3F). The consistent presence of these contaminating cells within the sorted MC pool from 6 donors indicates the necessity of including additional markers to identify human MCs under conditions where contaminating populations cannot be computationally removed, such as bulk RNA-seq or functional assays. The four remaining clusters, designated MC1–4 (Fig. 3B), all strongly expressed the MC proteases tryptase (*TPSAB1*) and CPA3 (*CPA3*) and similar levels of transcripts encoding the histamine biosynthetic enzyme histidine decarboxylase (*HDC*) and the lipid mediator biosynthetic enzymes prostaglandin D<sub>2</sub> synthase (*HPGDS*), 5-lipoxygenase (*ALOX5*), and 5-lipoxygenase activating protein (*ALOX5AP*) (Fig. 3C). The MC1-MC3 clusters further

showed similar expression of a set of core transcripts highly enriched in nasal polyp MCs (22), including the MC granule core protein serglycin (*SRGN*) and the transcription factor GATA2 (*GATA2*) (Fig. 3D, top). Together, these observations indicated that MCs within the polyp environment share a core effector program enabling the generation of proteases, lipid mediators, and histamine.

Differential gene expression analysis between the four identified MC clusters indicated MC1-enriched expression of chymase (*CMA1*) and cathepsin G (*CTSG*) (Fig. 3D), consistent with subepithelial MC<sub>TC</sub> (Fig. 1I, Fig. S2). The MC2 cluster lacked enriched genes, while the MC3 cluster expressed minimal *CMA1* and *CTSG* and reduced levels of transcripts encoding both CD117 (*KIT*) and the high-affinity IgE receptor FcεR1α (*FCER1A*) compared with the MC1 cluster, consistent with epithelial MC<sub>T</sub> (Fig. 3D, Fig. 1H). The MC3 cluster was additionally enriched for *IL17RB*, encoding the receptor for the epithelial-associated cytokine IL25, and *GPR183*, encoding the chemotactic receptor EB12 (28, 29). Immunofluorescence confirmed co-localization of tryptase and EB12 within the epithelium, although not all MCs within the epithelium expressed detectable EB12 (Fig. S4). Unexpectedly, the MC4 cluster expressed transcripts involved in proliferation and DNA replication, including *TOP2A* (encoding DNA Topoisomerase IIA) and *MKI67* (encoding the cell cycle phase-associated protein KI67) (Fig. 3D, Supplementary Table 4).

We further observed that the transcriptional signatures associated with MC1 and MC3 (Supplementary Table 4) were expressed along gradients (Fig. 3E). These cluster-defining signatures exhibited negative correlation on a per-cell basis, with the MC2 cluster expressing low levels of each, suggesting an intermediate state (Fig. 3F, top). Cells within the proliferative cluster showed a range of MC1 and MC3 signature expression similar to that seen in the MC2 cluster, and the MC1 and MC3 signatures were again negatively correlated on a per cell basis (Fig. 3F, bottom). This suggested that the polyp MC<sub>TC</sub> (MC1) and MC<sub>T</sub> (MC3) transcriptional programs represented polarization states layered on a common shared transcriptome and that the proliferative population (MC4) shared transcriptional overlap with unpolarized MCs (MC2).

To better understand the transcriptional differences between the two polarized MC states, we directly compared the MC1 (MC<sub>TC</sub>) cluster to the MC3 (MC<sub>T</sub>) cluster. These populations exhibited differential expression of 282 transcripts (Wilcoxon,  $p_{adj} < 0.05$ ) (Fig. 3G, Supplementary Table 4). The MC1 (MC<sub>TC</sub>) cluster showed enhanced expression of chemokines (*CCL2*, *CCL3*, *CCL4*, *CKLF*), myeloid cell growth factors (*CSF1*, *CSF2*), the cytokine *IL13* and the lipid mediator biosynthetic enzyme *PTGS2* (Fig. 3H), suggesting they are poised to coordinate pro-inflammatory responses through several mechanisms. Although all MC clusters expressed transcript encoding the protease CPA3 (Fig. 3C), this was notably enriched within MC3 (MC<sub>T</sub>) cluster (Fig. 3G). MC3 additionally showed enhanced expression of *TNFSF10*, encoding TRAIL, which positively regulates airway inflammation and remodeling in murine models of asthma (30, 31), *FGL2*, which shifts DC and T cell interactions towards Th2 polarization (32) (Fig. 3H), and *IL17RB* (Fig. 3G), suggesting the potential for this population to modulate T2-driven responses within the epithelium and respond to epithelial-derived IL-25.

Previous studies have indicated that epithelial-derived factors inhibit IgE-dependent MC activation (33, 34). Accordingly, the MC<sub>T</sub> cluster showed reduced expression of components of the FcεR1 complex (*FCER1A*, *MS4A2*, *FCER1G*) and the downstream regulator *BTK* (Fig. 3I). In contrast, no significant difference was observed for expression of the IL-33 receptor *IL1RL1* (Supplementary Table 4). To test if activation states of polyp MC<sub>TC</sub> and MC<sub>T</sub> differed more broadly, we constructed MC activation transcriptional signatures based on existing microarray datasets evaluating murine bone marrow-derived MC activation (35) (Supplementary Table 2). We found that MC1 (MC<sub>TC</sub>) expressed the highest levels of transcript signatures specific to IgE-mediated activation, specific to IL-33-mediated activation, and commonly upregulated by both signals, while the MC3 (MC<sub>T</sub>) exhibited decreased expression and MC2 expressed intermediate levels (Mann-Whitney,  $p < 1 \times 10^{-11}$  for all comparisons) (Fig. 3J). Thus, polyp MC<sub>TC</sub> are activated at baseline, reflected in their increased cytokine and chemokine expression, and the intermediate MC2 exhibit activation despite a lack of polarization.

### Identification of a distinct MC<sub>T</sub> phenotype associated with respiratory tract inflammation.

Several genes identified as part of the MC<sub>T</sub> transcriptome, including *GPR183*, *IL17RB* and *CD38*, were not previously associated with human MCs. To determine whether this phenotype was restricted to nasal polyposis or associated with broader inflammatory conditions, we evaluated three lung scRNA-seq datasets from patients with fibrosis included within the idiopathic pulmonary fibrosis (IPF) cell atlas (36). These datasets included analyses of IPF and interstitial lung disease (ILD) versus healthy control (37), IPF and chronic obstructive pulmonary disease (COPD) versus healthy control (38), and IPF versus healthy control (39). Notably, prior studies have found increased expression of transcripts encoding the T2 cytokine signaling pathway and the MC protease *CPA3* in IPF (40). Independent analysis of each of the three datasets identified a prominent *TPSAB1*-expressing MC cluster (Fig. S5). MCs from each dataset were separately reclustered, and substantial disease-associated MC heterogeneity was noted within each (Fig. 4A–C, left panels, supplementary table 5). We observed a cluster of MCs within each dataset exhibiting significant enrichment for *CD38*, *GPR183*, *IL17RB* (Fig. 4 A–C center panels, polygon gate), and further noted MCs co-expressing the proliferation-associated genes *MKI67* and *TOP2A* in two of the three datasets (Fig. 4 A–C center panels, circle gate). Across each dataset, the CD38<sup>high</sup> populations consisted predominantly of MCs from IPF or ILD (Fig. 4 A–C, left panels). We further identified a MC cluster significantly enriched for both *CD38* and *CPA3* (Fig. S6A, cluster outlined in black) in a re-analysis of a prior scRNA-seq study of lung biopsy samples from asthmatic vs controls (41), in which *IL17RB* and *GPR183* expression could also be observed, although neither reached statistical significance (Fig. S6B, Supplementary Table 5). A comparison of genes significantly enriched within the CD38<sup>high</sup> clusters across the three fibrosis datasets identified substantial transcriptional overlap, with 18 transcripts enriched in all three datasets, including *CPA3*, and 85 transcripts enriched within the CD38<sup>high</sup> cluster in at least two of the three datasets (Table 1; Wilcoxon,  $p < 0.05$ ). Notably, these transcripts overlapped with transcripts enhanced in both polyp MC<sub>T</sub> (19 transcripts) and the *CD38*-enriched asthma-associated cluster (38 transcripts), indicating a common inflammation-associated transcriptional program.



Expression of *IL17RB* by MCs in the lungs of patients with fibrosis and asthma and CRSwNP polyps suggested this transcript was regulated by disease-associated signals. Mouse studies have identified a central role for IL-4 in intraepithelial MC expansion (42, 43), and a re-analysis of our prior nasal polyposis scRNA-seq dataset indicated a significant correlation between polyp MC concentration and epithelial expression of an IL-4/IL-13-driven cytokine signature (22) (Fig. 4D). Notably, *IL4* expression in nasal polyposis was restricted to Th2A cells, while *IL13* was expressed by both Th2A cells and MCs (22). Further, re-analysis of scRNA-seq data from a single CRSwNP donor evaluated before and after six weeks of treatment with dupilumab, a monoclonal antibody directed against the IL-4 receptor, revealed markedly reduced *IL17RB* expression within the MC cluster compared with pre-treatment baseline but no change in expression of the MC<sub>T</sub>-associated transcript *GPR183* (Figure S7). Thus, we hypothesized that IL-4 directly influenced polyp MC<sub>T</sub>s.

To evaluate IL-4 regulation of the polyp MC<sub>T</sub> transcriptome, human cord blood-derived MCs (CBMC) were stimulated with IL-4 or vehicle for 96 hours and then analyzed via RNA-seq. IL-4 exerted a profound impact on the CBMC transcriptome (Supplementary table 6). Among the upregulated genes were 30 of 102 polyp MC<sub>T</sub>-enriched transcripts, including *IL17RB* and *CD38* but not *GPR183* (Fig. 4E, Supplementary table 6). Notably, IL-4 conditioning also downregulated 37 of 180 MC<sub>TC</sub>-enriched transcripts, including *CTSG* and *KIT* (Fig. 4F). The capacity for IL-4 to upregulate *IL17RB* was further confirmed through qPCR analysis (Fig. 4G). However, IL-4 stimulus also upregulated FcεR1 signaling components (Supplementary table 6) that were downregulated in polyp MC<sub>T</sub> (Fig. 3I), suggesting other signals additionally regulate the MC<sub>T</sub> transcriptome. Thus, our findings identified a distinct phenotype of MC<sub>T</sub> associated with respiratory inflammation and identified the potential for IL-4 signaling to regulate this phenotype.

### Recognition of significant MC<sub>TC</sub> heterogeneity across tissues.

While chymase-expressing MCs found in mucosal tissues during inflammation are termed MC<sub>TC</sub>, the relatedness of these cells to constitutive MC<sub>TC</sub> populations present in peripheral tissues such as the skin has not been addressed. Thus, we compared nasal polyp MCs to dermal MCs derived from a scRNA-seq study of healthy and diseased human skin biopsies from patients with psoriasis, alopecia, acne, leprosy, and granuloma annulare (44). Polyp MC1 (MC<sub>TC</sub>) and dermal MCs, canonically exhibiting an MC<sub>TC</sub> phenotype (5), both showed enhanced expression of *CMA1* relative to polyp MC1 (MC<sub>T</sub>), as well as a shared subset of receptors (*KIT*, *PLAUR*, *ICAM1*) and mediators (*LIF*, *CSF1*) (Fig. 5A). However, dermal MC<sub>TC</sub> lacked expression of other transcripts strongly expressed in polyp MCs and vice versa. Polyp MC1 (MC<sub>TC</sub>) were enriched in expression of chemokines (*CCL2*, *CCL3*, *CCL4*) and FcεR1α signaling pathway transcripts (*FCER1A*, *MS4A2*, *BTK*) relative to dermal MCs, but lacked expression of genes encoding the activating GPCRs CD88 (*C5AR1*) and MRGPRX2 (*MRGPRX2*), previously described as markers for MC<sub>TC</sub> in the skin and lung (45, 46). Supporting this observation, we found strong surface expression of MRGPRX2 on skin-derived MCs, but little to no expression on polyp MCs (Fig. 5B). To determine if the absence of these receptors reflected the polyp inflammatory environment a broader paradigm of MC<sub>TC</sub> heterogeneity, we conducted an independent analysis of an

existing scRNA-seq dataset containing distal (alveolar), medial and proximal (large bronchi) fractions of healthy lung developed by Travaglini et al (47). Following normalization, we identified a prominent *TPSAB1*-expressing MC cluster (Fig. 5C). Despite the presence of similar numbers of MCs expressing *CMA1* and *CTSG* in the distal and proximal lung, *MRGPRX2* expression could only be detected in the large airway (Fig. 5D). Although not reaching statistical significance, this observation suggests that MC<sub>TC</sub> exhibit heterogeneity even within a single tissue. *C5ARI*, encoding CD88, was only weakly detected in either lung compartment. These findings indicate considerable differences in the transcriptome of chymase-expressing MCs across tissues and inflammatory milieus, and further highlight the activated state of polyp MCs and their likely pathogenic contributions. Moreover, the findings further illustrate the vast extent of MC heterogeneity that is not reflected by conventional histochemical criteria.

### Identification of CD117 and CD38 cell surface expression patterns defining polyp MC phenotypes.

Among the transcripts enriched in MC3 (MC<sub>T</sub>) relative to MC1 (MC<sub>TC</sub>) clusters was *CD38* (Fig. 3G), suggesting a candidate cell surface marker that might further distinguish polyp MC subsets. Cell surface staining indicated virtually all CD117<sup>low</sup> epithelial MC<sub>T</sub>s exhibited high CD38 expression (Fig. 6A–B; red gate). Unexpectedly, CD38 expression also divided the heterogeneous CD117<sup>high</sup> subepithelial MC pool (Fig. 1C) into CD38<sup>high</sup>SSC<sup>low</sup> MCs (orange) and CD38<sup>neg</sup> MCs with a range of SSC (blue). Itgβ7<sup>high</sup> polyp MCs notably expressed CD38 (Fig. 6C). A subset of cells lacking both CD117 and CD38 (Fig. 6A) were likely the source of contaminants observed through scRNA-seq (Fig. S3). CD38<sup>high</sup>CD117<sup>high</sup> subepithelial MCs were also detected in CRSsNP tissue, however their relative abundance was significantly reduced when compared to CRSwNP and AERD polyps (Fig. 6D–E). No significant differences were observed in MC subset composition between CRSwNP and AERD. Thus, CD38 marks polyp epithelial MC<sub>T</sub> and Itgβ7-expressing MC, as well as a CD117<sup>high</sup> subepithelial MC subset significantly expanded in nasal polyps.

Enriched CD38 expression in CD117<sup>low</sup> MCs (Fig. 6A), and reduced *CD38* in MC1 relative to MC3 (Fig. 3G), suggested that CD117<sup>high</sup>CD38<sup>low</sup> subepithelial MCs were mature MC<sub>TC</sub>. Flow cytometry confirmed that CD117<sup>low</sup> intraepithelial MCs (red) lacked chymase expression (Fig. 6F), consistent with immunofluorescent staining (Fig. 1H), whereas subepithelial CD117<sup>high</sup>CD38<sup>low</sup> MCs (blue) were uniformly positive for chymase, indicating a MC<sub>TC</sub> phenotype (Fig. 6F–G). The CD38<sup>high</sup>CD117<sup>high</sup> MC gate included both chymase positive and negative cells (Fig. 6F). Similarly, staining with avidin, a reagent that binds to heparin sulfate (48) and specifically identifies human MC<sub>TC</sub> (49), was highest in subepithelial CD117<sup>high</sup>CD38<sup>low</sup> MC<sub>TC</sub> (blue), lowest in CD117<sup>low</sup>CD38<sup>high</sup> (red) epithelial MC<sub>T</sub>, and intermediate in CD117<sup>high</sup>CD38<sup>high</sup> MCs (yellow) (Fig. 6H–I). Thus, through surface marker expression and intracellular protease and heparin staining, we could identify mature intraepithelial MC<sub>T</sub> (CD117<sup>low</sup>CD38<sup>high</sup>; red) and subepithelial MC<sub>TC</sub> (CD117<sup>high</sup>CD38<sup>low</sup>; blue) and further identify a subepithelial population with an intermediate phenotype (CD117<sup>high</sup>CD38<sup>high</sup>; yellow), suggestive of the MC2 subset identified through scRNA-seq.

## Evaluation of in situ proliferation within human polyp MCs.

To integrate our transcriptional analysis with these flow cytometrically-defined MC subsets, we used CITE-seq (50) to simultaneously assesses RNA and surface protein expression on flow-sorted polyp MCs, using oligo-tagged antibodies directed against CD117, CD38 and Itg $\beta$ 7 (Fig. 7A). Clustering again identified the same four MC populations (Fig. 7B, Supplementary Table 4), indicating that MC<sub>TC</sub> (MC1) exhibited high surface CD117 and low surface CD38 while MC<sub>T</sub> (MC3) exhibited low surface CD117 and high surface CD38 (Fig. 7C). We further observed that the MC2 cluster exhibited intermediate surface CD117 and CD38 levels, confirming its identity as the flow cytometrically-defined CD38<sup>high</sup>CD117<sup>high</sup> population, and that the proliferating MC4 seen similarly exhibited elevated CD38 and CD117 levels. Surface Itg $\beta$ 7 was predominantly observed in the MC3 cluster (Fig. 7D), in agreement with the previously observed epithelial enrichment of Itg $\alpha$ E<sup>+</sup> $\beta$ 7<sup>+</sup> MCs (Fig. 2G), but scattered Itg $\beta$ 7 expression was also observed across all clusters. A direct comparison of Itg $\beta$ 7<sup>high</sup> and Itg $\beta$ 7<sup>low</sup> MCs within each cluster indicated little to no impact of Itg $\beta$ 7 expression on the MC transcriptome (Fig. S8).

Our CITE-seq observations suggested that the majority of proliferating MCs would be CD117<sup>high</sup>CD38<sup>high</sup> subepithelial MCs. Nuclear KI67 staining identified a distinct population of proliferating MCs (Fig. 7E), and while proliferation was observed across all three compartments, the majority of KI67<sup>+</sup> cells were CD117<sup>high</sup>CD38<sup>high</sup> subepithelial MCs (Fig. 7F). Combined with the detection of both MC<sub>T</sub> and MC<sub>TC</sub>-associated transcript signatures within the proliferating clusters detected through scRNA-seq (Fig. 3F), these findings suggest that the MC hyperplasia characteristic of human nasal polyposis is driven in part by in situ MC proliferation. Consistent with this hypothesis, we observed a significant increase in MC proliferation in the polyps of AERD patients relative to MC from CRSwNP donors (Fig. 7G), corresponding to the differences in polyp MC concentration between these two patient groups (Fig. 1B). We further noted a significant correlation between MC proliferation and peripheral blood eosinophilia across all polyp patients (Fig. 7H), indicating a link between MC proliferation and overall disease severity. Coupled with the previous observation that progenitor-like Itg $\beta$ 7-expressing MC were present at similar concentrations in AERD and CRSwNP (Fig. 2D), our findings suggest an important role for local proliferation in MC hyperplasia during T2 airway inflammation.

## Discussion

Our study provides a transcriptomic and flow cytometric characterization of MC hyperplasia during human airway inflammation, identifying proliferation as a driver of T2-associated non-neoplastic MC airway hyperplasia. We also observe that MC sensing and effector programs are closely linked to tissue microenvironments. The MC<sub>T</sub> and MC<sub>TC</sub> phenotypes in CRSwNP tissue display substantial cell surface differences and predominate in epithelial and subepithelial regions, respectively. Despite shared expression of a core transcriptome, they inhabit opposite poles of a transcriptional gradient, implying distinct functions for each. The CRSwNP MC<sub>T</sub> program, distinguished by expression of *CD38*, *IL17RB* and *GPR183*, is also observed within the lungs of IPF, ILD, and asthma patients. These MC<sub>T</sub> further express elevated *CPA3*, suggesting a link to the CPA3<sup>+</sup> MC<sub>T</sub>s previously reported in the

bronchial epithelium of asthmatics and esophagus of EoE patients (15–18). The CRSwNP MC<sub>TC</sub> program, enriched for proinflammatory cytokines and chemokines, differs from classical skin and noninflamed lung MC<sub>TC</sub>s by its lack of the MC<sub>TC</sub> markers MRGPRX2 and CD88 (*C5AR1*) (45, 51, 52). Both MC<sub>T</sub> and MC<sub>TC</sub> populations expand markedly in CRSwNP tissue, and even more so in AERD tissue, relative to CRSsNP controls. Based on these observations, we propose that these expanded mucosal T2-inflammation-associated MC subsets be reclassified as airway inflammatory MC<sub>T</sub> and MC<sub>TC</sub> (iMC<sub>T</sub> and iMC<sub>TC</sub>), respectively, distinguishing them from their counterparts in non-mucosal tissues and tissues with less T2 inflammation (Fig. S9).

The stark transcriptional differences between iMC<sub>T</sub> and iMC<sub>TC</sub> imply both distinct functions and distinct patterns of imprinting by tissue-associated factors. Both iMC<sub>TC</sub> and transitional MC clusters display enrichment for FcεRI- and IL-33-inducible transcripts characterized by chemokines (*CCL2*, *CCL3*, *CCL4*), cytokines (*IL13*), growth factors (*CSF1*, *CSF2*), and *PTGS2*, (encoding cyclooxygenase-2, required for PGD<sub>2</sub> generation). Thus, subepithelial MCs may respond to both innate (IL-33) and adaptive (IgE) immune pathways to provide mediators driving recruitment and activation of blood-born effector cells and conditioning the surrounding stroma. Although iMC<sub>T</sub> display lower levels of activation-associated transcripts, they uniquely express *IL17RB*, the receptor for the epithelial-derived T2 cytokine IL-25. Notably, *IL17RB* is also expressed by MCs in the lungs of IPF, ILD, and asthma patients, indicating it is part of a disease-associated human respiratory intraepithelial MC transcriptional program. Treatment of primary cord blood MCs with IL-4, a T2 cytokine required for murine intraepithelial MC hyperplasia during helminth infection and food allergy (42, 43), induces *IL17RB* expression along with other iMC<sub>T</sub> transcripts. While IL4 did not upregulate proliferation-associated transcripts in cord blood MCs, prior studies have shown that IL4 markedly amplifies SCF-dependent proliferation in human primary MCs from the intestine and peripheral blood (53, 54). The finding that treatment with the IL-4Rα blocking antibody dupilumab, highly efficacious for CRSwNP (55), sharply reduces *IL17RB* expression by the MC cluster further supports the concept that IL-4 contributes substantially to iMC<sub>T</sub> hyperplasia and function. Epithelial signatures of IL4/13 signaling correlated with MC concentration in our prior study of nasal polyposis (22), and this signature is also notably elevated in the lungs of asthmatics (41). Fibrosis patients similarly exhibit enhanced T2 cytokine pathway activation (40). Ultimately, an analysis of whether therapeutic interventions for polyposis and asthma, including monoclonal antibody blockade of IL-4/13 (56, 57), and CD117 inhibition (2) alter MC proliferation and transcriptional activity will allow definitive identification of tissue drivers of MC hyperplasia and differentiation.

MCs are thought to arise from rare agranular circulating CD34<sup>+</sup>Itgβ7<sup>+</sup> precursors (13). Although Itgβ7<sup>high</sup> MCs were enriched in both aspirin tolerant CRSwNP and AERD tissue compared with controls, these cells were CD34<sup>-</sup>, contained cytoplasmic granules and expressed tryptase, suggesting maturation. Although predominantly intraepithelial, Itgβ7<sup>high</sup> MCs could be found within all populations and were transcriptionally indistinguishable from Itgβ7<sup>-</sup> MCs within the same clusters. Thus, a portion of the MC population within nasal polyps, particularly iMC<sub>T</sub>, may arise directly from recruited MC<sub>p</sub>. Two additional clusters within the polyp MC pool were not expected based on prior histologic studies: one lacking signature transcripts, and one undergoing proliferation. Both clusters expressed low levels of

iMC<sub>T</sub> and iMC<sub>TC</sub> signature transcripts, suggesting they were developmentally intermediate between the two polarized populations. CITE-seq analysis linked these “intermediate” MCs to the prominent expanded CD117<sup>high</sup>CD38<sup>high</sup> MC pool, which by flow cytometry displayed variable chymase expression and avidin binding. CD117<sup>hi</sup>CD38<sup>hi</sup> MCs accounted for 40–60% of CRSwNP tissue MCs, were present (although reduced) in CRSsNP controls, and were enriched for proliferation. Moreover, Ki67<sup>+</sup> MCs were substantially elevated in AERD and correlated with blood eosinophilia, a marker of T2 cytokine production (58). It is thus likely that MC hyperplasia results from a combination of Itgβ7<sup>high</sup> MCP recruitment and *in situ* MC proliferation, with the contributions from the latter being magnified in more severe disease. The combination of polarization and proliferation suggests a similar paradigm to that observed with monocytes, which have innate effector capacity, mature and take on distinct effector programs in response to local inflammatory signals, and are maintained within tissue through local IL-4 driven proliferation (59, 60).

Although our transcriptomic analysis strongly suggests the intermediate CD117<sup>hi</sup>CD38<sup>hi</sup> MCs contributes to both iMC<sub>T</sub> and iMC<sub>TC</sub> hyperplasia, future studies will be required to determine if these cells are indeed capable of polarizing towards both observed MC effector phenotypes. Furthermore, although CD117<sup>hi</sup>CD38<sup>hi</sup> MCs express similar levels of lipid mediator biosynthetic enzymes as iMC<sub>T</sub> and iMC<sub>TC</sub>, we were unable to directly assess their ability to generate inflammatory mediators. As a previous transcriptomic analysis of human circulating MCP indicated that even agranular progenitors were enriched for *HGPDS* expression(13), it will be important to understand whether this means that MC lineage cells are capable of producing lipid mediators at all phases of development or if, instead, the enzymes themselves are only translated following maturation. It is also unclear what role the three primary transcripts found to associate with the iMC<sub>T</sub> across disease states, *CD38*, *GPR183* and *IL17RB*, may play in MC biology. EB12, encoded by *GPR183*, has been shown to participate in B cell and DC localization within tissues(28, 29, 61), suggesting a similar role in MCs. While it is less clear what effects CD38 and IL17RB may have on iMC<sub>T</sub> biology, the identification of IL-4 as a signal capable of upregulating both receptors *in vitro* provides critical insight for future studies exploring their roles.

In summary, through transcriptional and flow cytometric characterization of MC hyperplasia in T2 airway inflammation we identify transcriptionally and phenotypically distinct MC subsets that potentially emerge from a novel, proliferative intermediate MC subtype. The polarized MC subtypes emerging from the intermediate subtype assume distinct transcriptional and morphologic characteristics based on their tissue microenvironment. The expansion of the intermediate subtype may be a critical determinant of disease severity, in turn reflecting perturbations in the surrounding stroma, mitogenic cytokines and inflammatory mediators that likely exert a substantial additional influence on the MCs within each tissue microenvironment. Uncovering the drivers of this proliferative response and the tissue signals responsible for directing MC polarization will be critical for identifying therapeutic targets for T2 inflammation-associated diseases in which MC hyperplasia is prominent and MC effector responses play an important role.

## Methods

### Study participants and design

Ethmoid sinus tissue was obtained from participants between the ages of 21 and 76 years, recruited from the Brigham and Women's Hospital (Boston, Massachusetts) Allergy and Immunology clinic and Otolaryngology clinic between May 2014 and September 2020 (Supplementary Table 1). This study was approved by the Institutional Review Board (IRB), with all study participants providing written consent. Tissue was collected at the time of elective endoscopic sinus surgery from patients with physician-diagnosed CRSwNP or CRSsNP. Patients with polyps included diagnoses of both aspirin-tolerant CRSwNP and aspirin-intolerant AERD. A diagnosis of AERD was suspected for patients with asthma, nasal polyposis, and a history of respiratory reaction following usage of cyclooxygenase inhibitors, and all diagnoses were confirmed via graded oral challenge with aspirin. Subjects with cystic fibrosis and unilateral polyps were excluded. After no distinctions in MC characteristics between the two disease endotypes were noted beyond MC concentration and proliferation, the data were combined unless otherwise noted. Analysis was conducted in a non-blinded manner. Peripheral blood was obtained from patients without ethmoid sinus disease under the same protocol. De-identified human skin samples were obtained from the Brigham and Women's Hospital surgical department under a separate IRB-approved protocol.

### Flow cytometry, cell sorting and analysis

Single-cell suspensions were resuspended in FACS Buffer (HBSS, Ca/Mg-free (ThermoFisher) supplemented with 2% FCS and 1 mM EDTA) prior to flow cytometric staining. MCs were sorted on a Sony SH800 cell sorter using Sony Cell Sorter Software (SeqWell) or a BD FACSAria Fusion cell sorter using BD FACSDiva software (Histologic assessment). For all flow cytometry not involving cell sorting, cells were analyzed on a BD LSRII Fortessa or BD CANTO-II using BD FACSDiva software.

### Cytologic analysis

To minimize cell loss, sorted MCs were placed on a glass slide at a concentration of 1,000 cells in 10  $\mu$ l. Slides were quickly dried using a plate warmer at the lowest setting. For granule visualization, cells were stained with 100  $\mu$ l toluidine blue solution (94.2% H<sub>2</sub>O, 5.8% concentrated HCl, 0.5 g toluidine blue) for 30 seconds and washed using DI H<sub>2</sub>O. For protease immunostaining, cells were fixed with Carnoy's fixative as previously described(62).

### Histologic analysis

Nasal polyp biopsies were fixed in 4% paraformaldehyde, embedded in paraffin, and 6  $\mu$ m sections were cut for histologic analysis. Tissue sections were deparaffinized and rehydrated. Slides were quenched with 1 mg/ml sodium borohydride 3 times on ice for 10 min each. Antigen retrieval was performed with Target Retrieval Solution, pH 9 (Agilent Technologies, Inc) at 97°C for 35 min. Microscopy and photography were done using OLYMPUS BX 41 system microscope and OLYMPUS DP 71 camera.

### scRNA-seq and analysis

After obtaining single-cell suspensions from freshly resected sinus tissue, we utilized the Seq-Well platform for massively parallel scRNA-seq to capture transcriptomes of sorted MCs on barcoded mRNA capture beads (27), described in greater detail in supplemental methods. Read alignment was performed as in Macosko et al (63). UMI-collapsed data was utilized as input into Seurat (64) (<https://github.com/satijalab/seurat>) for analysis. Before incorporating a sample into our merged dataset, we individually inspected the cell-by-gene matrix of each as a Seurat object. For analysis of all sequenced samples, we merged UMI matrices across all genes detected to generate a matrix containing all cells detected (n= 8,228 cells and 25,104 genes). This table was then utilized to setup the Seurat object in which any cell with at least 200 unique genes was retained and any gene expressed in at least 3 cells was retained. Cells with greater than 10% mitochondrial genes or UMI counts less than 200 and greater than 2500 were removed from analysis. The total number of cells passing these filters captured across all patients was 7,355 cells with 18,102 genes, averaging 2,699 cells per sample with a range between 221 cells and 2,359 cells. Before performing dimensionality reduction, data was log-normalized with a scale factor of 10,000, scaled and centered, and a list of 2,000 most variable genes was generated by using the vst selection method. We then performed principal component analysis using variable genes. A shared nearest neighbor (SNN) graph and uniform manifold approximation and projection embedding (UMAP), were constructed using the first 9 principal components based on the inflection point of the elbow plot. We used FindClusters (which utilizes a SNN modularity optimization-based clustering algorithm) with a resolution of 0.4 and RunUMAP using default settings to identify 10 clusters across the 6 input samples. Additional analysis information can be found in supplemental methods.

### CITE-seq computational pipelines and analysis

CITE-seq methodology can be found in the supplemental methods section. For analysis, CITE-seq tag counting and demultiplexed ADT reads were processed using the CITE-seq-Count package version 1.4.2. Reads were matched with their corresponding ADT sequences and assigned to cell barcodes within a whitelist of cells that contained between 200 and 2500 mRNA UMIs. Once binned by cell barcode, ADT reads were collapsed by their 8-bp UMI.

For data analysis, one Seurat object was created per sample. Cells with UMI counts less than 200 and greater than 2500 were removed from the analysis. For both experiments, data was log normalized with a scale factor of 10,000, scaled and centered, and the 2,000 most variable transcripts were determined using the FindVariableFeatures function. Tag counts for ADTs were scaled and centered before center log ratio normalization (CLR). Contaminating cell populations were computationally removed from each object as described in Cell Type Identification, and the two experiments were integrated within Seurat using the Harmony software package (65). For constructing a SNN graph and UMAP embedding, we utilized the first 10 principal components, reflecting the inflection point of the elbow plot. We used FindClusters with a resolution of 0.4 and RunUMAP using default settings to identify 4 clusters across the 2 input samples.

## Statistical analysis

Number of samples included in analyses are listed throughout figure legends and represent distinct biological samples. Source data is provided in Supplementary table 7. No samples or cells meeting quality thresholds were excluded from analyses. Statistical analyses were performed using GraphPad Prism v7.0c and Seurat 3.0.1 implemented in RStudio. Some violin plots were generated using Graphpad Prism using data exported from Seurat to allow display of median and quartile values. Paired t tests were used when comparing protein expression across multiple subsets within individual patients and are indicated by linked points. Unpaired 2-tail t-tests were for comparisons of data found to be normally distributed using the D'Agostino & Pearson test. For all other data, the Mann Whitney U tests was used for comparisons.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements

We thank E. Lewis and N. Hallen for technical support in preparing tissue digests, the Broad Genomics Platform and Robert Chase of the BWH Channing Division of Network Medicine for RNA-seq assistance with CBMCs, members of the Shalek Laboratory for experimental and computational advice, and M. Morrison and F. Al Haddad for administrative support.

## Funding

J.A.B. was supported by NIH grants R37AI052353, R01AI136041, R01AI130109, R01HL136209, and U19AI095219; N.A.B. by NIH grants R01HL120952, R01AI134989, U19AI095219, and Steven and Judy Kaye Young Innovators Award; A.K.S. by the Searle Scholars Program, the Beckman Young Investigator Program, the Pew-Stewart Scholars Program for Cancer Research, a Sloan Fellowship in Chemistry, the NIH (5U24AI118672), the Bill and Melinda Gates Foundation.; T.M.L. by NIH grants R01HL128241 and U19AI095219; M.C.N acknowledges funding from the Netherlands Lung Foundation project no. 5.1.14.020 and 4.1.18.226, and the European Union's H2020 Research and Innovation Program under grant agreement no. 874656 (discovAIR) and grant number CZF2019-002438 from the Chan Zuckerberg Initiative Foundation awarded to the HCA Lung Seed Network. K.M.B. was supported by NIH AADCRC Opportunity Fund Award U19AI070535; J.O.M J.O.M is a New York Stem Cell Foundation – Robertson Investigator. J.O.M was supported by the Richard and Susan Smith Family Foundation, the HHMI Damon Runyon Cancer Research Foundation Fellowship (DRG-2274-16), the AGA Research Foundation's AGA-Takeda Pharmaceuticals Research Scholar Award in IBD – AGA2020-13-01, the HDDC Pilot and Feasibility P30 DK034854, the Food Allergy Science Initiative, and The New York Stem Cell Foundation.; D.F.D. was supported by T32 AI007306 (to J.A.B.), NIH AADCRC Opportunity Fund Award U19AI070535, K22 AI146281, and by generous contributions from the Vinik family.

## References


1. Mukai K, Tsai M, Saito H, Galli SJ, Mast cells as sources of cytokines, chemokines, and growth factors. *Immunol Rev*282, 121–150 (2018). [PubMed: 29431212]
2. Cahill KNet al., KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. *N Engl J Med*376, 1911–1920 (2017). [PubMed: 28514613]
3. Voehringer D, Protective and pathological roles of mast cells and basophils. *Nat. Rev. Immunol.* 13, 362–375 (2013). [PubMed: 23558889]
4. Andersson CK, Mori M, Bjermer L, Lofdahl CG, Erjefalt JS, Novel site-specific mast cell subpopulations in the human lung. *Thorax*64, 297–305 (2009). [PubMed: 19131451]
5. Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB, Two types of human mast cells that have distinct neutral protease compositions. *Proc Natl Acad Sci U S A*83, 4464–4468 (1986). [PubMed: 3520574]



6. Gentek Ret al., Hemogenic Endothelial Fate Mapping Reveals Dual Developmental Origin of Mast Cells. *Immunity*48, 1160–1171 e1165 (2018). [PubMed: 29858009]
7. Li Zet al., Adult Connective Tissue-Resident Mast Cells Originate from Late Erythro-Myeloid Progenitors. *Immunity*49, 640–653 e645 (2018). [PubMed: 30332630]
8. Gurish MF et al., Intestinal mast cell progenitors require CD49 $\beta$ 7 (alpha4beta7 integrin) for tissue-specific homing. *J Exp Med*194, 1243–1252 (2001). [PubMed: 11696590]
9. Abonia JP et al., Alpha-4 integrins and VCAM-1, but not MAdCAM-1, are essential for recruitment of mast cell progenitors to the inflamed lung. *Blood*108, 1588–1594 (2006). [PubMed: 16670268]
10. Bankova LG, Dwyer DF, Liu AY, Austen KF, Gurish MF, Maturation of mast cell progenitors to mucosal mast cells during allergic pulmonary inflammation in mice. *Mucosal Immunol*8, 596–606 (2015). [PubMed: 25291985]
11. Dwyer DF, Barrett NA, Austen KF, Immunological Genome Project C, Expression profiling of constitutive mast cells reveals a unique identity within the immune system. *Nat Immunol*17, 878–887 (2016). [PubMed: 27135604]
12. Xing W, Austen KF, Gurish MF, Jones TG, Protease phenotype of constitutive connective tissue and of induced mucosal mast cells in mice is regulated by the tissue. *Proc Natl Acad Sci U S A*108, 14210–14215 (2011). [PubMed: 21825171]
13. Dahlin JSet al., Lin- CD34<sup>hi</sup> CD117<sup>int</sup>/hi FcepsilonR1<sup>+</sup> cells in human blood constitute a rare population of mast cell progenitors. *Blood*127, 383–391 (2016). [PubMed: 26626992]
14. Zheng S, Papalexi E, Butler A, Stephenson W, Satija R, Molecular transitions in early progenitors during human cord blood hematopoiesis. *Mol Syst Biol*14, e8041 (2018). [PubMed: 29545397]
15. Dougherty RH et al., Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma. *J Allergy Clin Immunol*125, 1046–1053 e1048 (2010). [PubMed: 20451039]
16. Balzar Set al., Mast cell phenotype, location, and activation in severe asthma: data from the severe asthma research program. *Am. J. Respir. Crit. Care Med*183, 299–309 (2011). [PubMed: 20813890]
17. Takabayashi Tet al., Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps. *J. Allergy Clin. Immunol.* 130, 410–420 e415 (2012). [PubMed: 22534535]
18. Abonia JP et al., Involvement of mast cells in eosinophilic esophagitis. *J Allergy Clin Immunol*126, 140–149 (2010). [PubMed: 20538331]
19. Brightling CE et al., Mast-cell infiltration of airway smooth muscle in asthma. *New England Journal of Medicine*346, 1699 (2002).
20. Siddiqui Set al., Airway hyperresponsiveness is dissociated from airway wall structural remodeling. *J Allergy Clin Immunol*122, 335–341, 341 e331–333 (2008). [PubMed: 18572228]
21. Finotto S, Dolovich J, Denburg JA, Jordana M, Marshall JS, Functional heterogeneity of mast cells isolated from different microenvironments within nasal polyp tissue. *Clin Exp Immunol*95, 343–350 (1994). [PubMed: 7508349]
22. Ordovas-Montanes Jet al., Allergic inflammatory memory in human respiratory epithelial progenitor cells. *Nature*560, 649–654 (2018). [PubMed: 30135581]
23. White AA, Stevenson DD, Aspirin-Exacerbated Respiratory Disease. *N Engl J Med*379, 1060–1070 (2018). [PubMed: 30207919]
24. Buchheit KMet al., Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease. *J Allergy Clin Immunol*137, 1566–1576 e1565 (2016). [PubMed: 26691435]
25. Cepek KLet al., Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. *Nature*372, 190 (1994). [PubMed: 7969453]
26. Berlin Cet al., Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. *Cell*74, 185 (1993). [PubMed: 7687523]
27. Gierahn TMet al., Seq-Well: portable, low-cost RNA sequencing of single cells at high throughput. *Nat Methods*14, 395–398 (2017). [PubMed: 28192419]

28. Hannedouche Set al., Oxysterols direct immune cell migration via EB12. *Nature*475, 524–527 (2011). [PubMed: 21796212]
29. Liu Cet al., Oxysterols direct B-cell migration through EB12. *Nature*475, 519–523 (2011). [PubMed: 21796211]
30. Collison Aet al., Tumor necrosis factor-related apoptosis-inducing ligand regulates hallmark features of airways remodeling in allergic airways disease. *Am J Respir Cell Mol Biol*51, 86–93 (2014). [PubMed: 24484417]
31. Weckmann Met al., Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease. *Nat Med*13, 1308–1315 (2007). [PubMed: 17934471]
32. Shalev Iet al., Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis. *J Immunol*180, 249–260 (2008). [PubMed: 18097026]
33. Martin Net al., Primary human airway epithelial cell-dependent inhibition of human lung mast cell degranulation. *PLoS One*7, e43545 (2012). [PubMed: 22970103]
34. Hsieh FHet al., Human airway epithelial cell determinants of survival and functional phenotype for primary human mast cells. *Proc Natl Acad Sci U S A*102, 14380–14385 (2005). [PubMed: 16186496]
35. Chhiba KD, Hsu CL, Berdnikov S, Bryce PJ, Transcriptional Heterogeneity of Mast Cells and Basophils upon Activation. *J Immunol*198, 4868–4878 (2017). [PubMed: 28476932]
36. Neumark N. e. a.. ([www.ipfcellatlas.com](http://www.ipfcellatlas.com), 2019).
37. Habermann ACet al., Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis. *Sci Adv*6, eaba1972 (2020). [PubMed: 32832598]
38. Adams TSet al., Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis. *Sci Adv*6, eaba1983 (2020). [PubMed: 32832599]
39. Morse Cet al., Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis. *Eur Respir J*54, (2019).
40. Murray LAet al., Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. *Am J Respir Cell Mol Biol*50, 985–994 (2014). [PubMed: 24325475]
41. Vieira Braga FAet al., A cellular census of human lungs identifies novel cell states in health and in asthma. *Nat Med*25, 1153–1163 (2019). [PubMed: 31209336]
42. Burton OTet al., Direct effects of IL-4 on mast cells drive their intestinal expansion and increase susceptibility to anaphylaxis in a murine model of food allergy. *Mucosal Immunol*6, 740–750 (2013). [PubMed: 23149659]
43. Madden KBet al., Role of STAT6 and mast cells in IL-4- and IL-13-induced alterations in murine intestinal epithelial cell function. *J Immunol*169, 4417–4422 (2002). [PubMed: 12370375]
44. Hughes TKet al., Second-Strand Synthesis-Based Massively Parallel scRNA-Seq Reveals Cellular States and Molecular Features of Human Inflammatory Skin Pathologies. *Immunity*53, 878–894 e877 (2020). [PubMed: 33053333]
45. Oskeritzian CAet al., Surface CD88 functionally distinguishes the MCTC from the MCT type of human lung mast cell. *J. Allergy Clin. Immunol*115, 1162–1168 (2005). [PubMed: 15940129]
46. Fujisawa Det al., Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. *J Allergy Clin Immunol*134, 622–633 e629 (2014). [PubMed: 24954276]
47. Travaglini KJet al., A molecular cell atlas of the human lung from single-cell RNA sequencing. *Nature*587, 619–625 (2020). [PubMed: 33208946]
48. Kett WCet al., Avidin is a heparin-binding protein. Affinity, specificity and structural analysis. *Biochim Biophys Acta*1620, 225–234 (2003). [PubMed: 12595093]
49. Weidner N, Austen KF, Heterogeneity of mast cells at multiple body sites. Fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content. *Pathol Res Pract*189, 156–162 (1993). [PubMed: 8321743]
50. Stoeckius Met al., Simultaneous epitope and transcriptome measurement in single cells. *Nat Methods*14, 865–868 (2017). [PubMed: 28759029]

51. Motakis E et al., Redefinition of the human mast cell transcriptome by deep-CAGE sequencing. *Blood*123, e58–67 (2014). [PubMed: 24671954]
52. Fureder Wet al., Differential expression of complement receptors on human basophils and mast cells. Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells. *J. Immunol*155, 3152–3160 (1995). [PubMed: 7673728]
53. Bischoff SC et al., IL-4 enhances proliferation and mediator release in mature human mast cells. *Proc Natl Acad Sci U S A*96, 8080–8085 (1999). [PubMed: 10393951]
54. Kulka M, Metcalfe DD, High-resolution tracking of cell division demonstrates differential effects of TH1 and TH2 cytokines on SCF-dependent human mast cell production in vitro: correlation with apoptosis and Kit expression. *Blood*105, 592–599 (2005). [PubMed: 15367434]
55. Bachert Cet al., Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. *Lancet*394, 1638–1650 (2019). [PubMed: 31543428]
56. Wenzel Set al., Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. *Lancet*388, 31–44 (2016). [PubMed: 27130691]
57. Ortega HGet al., Mepolizumab treatment in patients with severe eosinophilic asthma. *N. Engl. J. Med*371, 1198–1207 (2014). [PubMed: 25199059]
58. Walker Cet al., Cytokine control of eosinophils in pulmonary diseases. *J Allergy Clin Immunol*94, 1262–1271 (1994). [PubMed: 7798567]
59. Jenkins SJet al., Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. *Science*332, 1284–1288 (2011). [PubMed: 21566158]
60. Gordon S, Martinez FO, Alternative activation of macrophages: mechanism and functions. *Immunity*32, 593–604 (2010). [PubMed: 20510870]
61. Yi T, Cyster JG, EB12-mediated bridging channel positioning supports splenic dendritic cell homeostasis and particulate antigen capture. *Elife*2, e00757 (2013). [PubMed: 23682316]
62. Laidlaw TMet al., Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcepsilonRI. *J Allergy Clin Immunol*127, 815–822e811–815 (2011). [PubMed: 21281958]
63. Macosko EZ et al., Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets. *Cell*161, 1202–1214 (2015). [PubMed: 26000488]
64. Satija R, Farrell JA, Gennert D, Schier AF, Regev A, Spatial reconstruction of single-cell gene expression data. *Nat Biotechnol*33, 495–502 (2015). [PubMed: 25867923]
65. Korsunsky Iet al., Fast, sensitive and accurate integration of single-cell data with Harmony. *Nat Methods*16, 1289–1296 (2019). [PubMed: 31740819]



**Figure 1: Phenotypic characterization of sinus MC hyperplasia**

(A) Flow identification of human sinus MCs. (Additional replicates and full gating in Figure S1).

(B) MC quantification as percentage of CD45<sup>+</sup> (left) or total cells (right) in indicated patient groups (n=6–12 donors/group). \*, p<0.05; \*\*, p<0.01 (Mann-Whitney).

(C) Representative plots showing MC heterogeneity in nasal polyp (left) or CRSsNP tissue (right).

(D) MC phenotype in polyp epithelium (left), whole polyp (center) with overlay (right). Red: epithelium; Black: whole polyp. Representative of five donors.


(E) Gating distinguishing epithelial MCs (CD117<sup>low</sup> SSC<sup>low</sup>, red) from subepithelial MCs (CD117<sup>high</sup>, blue) in epithelial fraction (left panel) vs unfractionated polyp (right panel)

(F) Quantification of epithelial and subepithelial MCs in fractionated epithelium and unfractionated polyp (n=5 donors); \*, p<0.05 (paired t-test).

(G) FcεR1α expression of epithelial (red) and subepithelial MCs (blue) with quantification (right). Lines denote paired observations (n=24 donors); \*\*\*\*, p<5 × 10<sup>-5</sup> (paired t-test)

(H) Toluidine blue (left) and protease immunophenotyping (right) of sorted CD117<sup>low</sup> MCs. Two examples provided to show heterogeneity. Green: tryptase; Red: chymase; Yellow: colocalization; Blue: nucleus.

(I) Toluidine blue (left) and protease immunophenotyping (right) of CD117<sup>high</sup> MCs. Two examples provided to show heterogeneity. Green: tryptase; Red: chymase; Yellow: colocalization; Blue: nucleus.



**Figure 2: Identification polyp MCs with a progenitor-like cell surface phenotype**

(A) Identification of nasal polyps  $SSC^{low}Itg\beta7^{high}$  MCs (left). CD117 and SSC expression on  $Itg\beta7^{high}$  MC (magenta) relative to all polyp MCs (grey) (right).

(B) Toluidine blue (left) and protease immunophenotype (right) of sorted  $Itg\beta7^{high}$  polyp MCs. Green: trypase; Red: chymase; Blue: nucleus


(C) Representative flow plot of  $Itg\beta7$  expression on CRSsNP MCs.

(D) Quantification of  $Itg\beta7^{high}$  MCs as a percentage of total MCs in CRSsNP, CRSwNP and AERD. \*\*,  $p < 0.01$  (Mann-Whitney).

(E) CD34 expression on polyp  $Itg\beta7^{high}$  MCs (magenta) and circulating  $MC_P$  (turquoise) vs isotype (grey), representative of three independent donors. (Magenta and grey are superimposed).

(F) Integrin expression on circulating  $MC_P$  (left) and polyp  $Itg\beta7^{high}$  MCs (right), each representative of three separate donors.

(G) Distribution of polyp  $\alpha E^{high}$  (green) and  $\alpha E^{-}$  (purple)  $Itg\beta7^{high}$  MCs distribution within the epithelial vs subepithelial gates (left) as in Fig. 1E, with quantification (right). \*,  $p < 0.05$  (paired t-test).



**Figure 3: scRNA-seq identification of transcriptionally distinct polyp MC subsets**

(A) Schematic representation for scRNA-seq analysis of 7,355 cells sorted polyp MCs (Fig. S1) (n=6 donors).

(B) Uniform Manifold Approximation and Projection (UMAP) depiction of MC clusters. (Fig. S3 depicts identification of MC vs contaminating clusters).


(C) MC expression of canonical MC transcripts.

(D) Common (top rows) and cluster-enriched transcripts (columns show donor-averaged row-normalized expression).  $p_{adj} < 3.1 \times 10^{-29}$  for cluster enriched genes (Wilcoxon).

(E) Polyp MC expression of MC1 and MC3 signatures (% of transcripts/cell).

(F) Per-cell expression of MC1 and MC3 signatures across all clusters (top) and MC4 alone (bottom). (correlation r-value).

- (G)** Differentially expressed transcripts between polyp MC<sub>TC</sub> (MC1) and MC<sub>T</sub> (MC3), (donor averaged, row normalized);  $p_{\text{adj}} < 6 \times 10^{-9}$  (Wilcoxon).
- (H)** Immunomodulatory transcript expression in polyp MC<sub>TC</sub> and MC<sub>T</sub>, (donor averaged, row normalized);  $p_{\text{adj}} < 7 \times 10^{-17}$  (Wilcoxon).
- (I)** FcεR1 signaling pathway expression in polyp MC<sub>TC</sub> and MC<sub>TC</sub> (donor averaged, row normalized);  $p_{\text{adj}} < 8 \times 10^{-4}$  (Wilcoxon).
- (J)** Expression of transcript scores driven by IgE signaling, IL33 signaling, or shared by both stimuli across the MC1–3 clusters. (lines denote median and quartiles)  $p^{***}$ ,  $p < 1 \times 10^{-10}$ ,  $***$ ,  $p < 1 \times 10^{-15}$  (Mann-Whitney); Cohen's effect size for MC1 vs. MC3: 0.60 (IgE), 0.79 (IL33), and 1.52 (shared).



**Figure 4: Characterization of an IL-4-elicited MC<sub>T</sub> phenotype enriched in diseased human lung samples.**

(A-C) Re-clustering of MCs from three scRNA-seq datasets accessed through the human IPF atlas: (A) control, IPF and ILD; (B) control, IPF and COPD; and (C) control and IPF. Clustering for each dataset indicated a population (polygon gate) that was statistically enriched for the polyp MC3-associated transcripts *IL17RB*, *CD38*, and *GPR183* (center panels) and predominantly composed of MCs from diseased tissue relative to healthy (left panels). Circle gate indicates MCs co-expressing the proliferation-associated genes *MKI67* and *TOP2A*.




**(D)** Correlation analysis of polyp scRNA-seq epithelial IL-4/13-induced signature expression, (donor averaged) versus scRNA-seq defined MC percentage for each donor.  $p < 0.001$ .

**(E)** MC3-enriched transcripts (Supplementary table 4) upregulated in two technical replicate CBMC samples by 96-hour IL-4 stimulus (row normalized expression). Top half:  $FDR < 0.1$ , bottom half (indicated by purple line):  $P < 0.05$  (DESeq2).

**(F)** MC1-enriched transcripts (supplemental table 4) downregulated in two technical replicate CBMC samples by 96 hours IL-4 stimulus (row normalized expression). Top half:  $FDR < 0.1$ , bottom half (indicated by purple line):  $P < 0.05$  (DESeq2).

**(G)** CBMCs *IL17RB* expression (qPCR) following 72-hour stimulus with vehicle or IL-4, (n=4 biologic replicates across three independent experiments), \* indicates  $p < 0.05$  (paired t-test).



**Figure 5: Identification of MC<sub>TC</sub> heterogeneity across tissues**

(A) Transcripts shared between diseased and control skin MCs and polyp MC<sub>TC</sub> (top) vs. enriched in skin MCs (upper middle), polyp MC<sub>T</sub> (lower middle), or polyp MC<sub>TC</sub> (bottom) (donor averaged, row normalized).

(B) Representative analysis of MRGPRX2 expression (red) on nasal poly MCs (left) and skin MCs (right) relative to isotype (grey). Staining representative of 3 donors per group.

(C) Identification of MCs based on *TPSAB1* expression within a scRNAseq dataset of healthy human lung tissue containing samples from distal, medial and proximal lung generated by Travaglini *et al*(47).


**(D)** Violin plots showing expression of the MC<sub>TC</sub>-associated transcripts *CMA1*, *CTSG*, *MRGPRX2*, and *C5AR1* in healthy human lung. No displayed transcripts were significantly differentially expressed between distal and proximal lung, MRGPRX2 expression was only observed in proximal lung.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 6: CD38 expression marks nasal polyp MC<sub>T</sub> and an unpolarized intermediary subset**

(A) Representative plot showing nasal polyp MC (gated as in Fig. S1) expression of CD38 and CD117. Arrow indicates sequential gating.

(B) SSC vs CD117 profile of CD38<sup>high</sup> epithelial MCs (red), CD38<sup>high</sup> subepithelial MCs (orange) and CD38<sup>low</sup> subepithelial MCs (blue).

(C) Representative plot showing CD38 and CD117 expression in Itgβ7<sup>high</sup> MCs.

(D) Representative plot of MC CD38 and CD117 expression in CRSsNP control tissue.


(E) Quantification of CD38<sup>high</sup>CD117<sup>low</sup> MC<sub>T</sub> (red), CD38<sup>high</sup>CD117<sup>high</sup> intermediate MCs (orange) and CD38<sup>low</sup>CD117<sup>high</sup> MC<sub>TC</sub> (blue) in sinus tissue of patients with CRSsNP (closed circles), CRSwNP (open squares), or AERD (closed triangles). \*\* indicates p<0.01 (Mann-Whitney)

(F) Intracellular chymase expression in epithelial MCs (red), CD38<sup>high</sup> subepithelial MCs (orange), and CD38<sup>low</sup> subepithelial MCs (blue) versus isotype (grey).

(G) Quantification of chymase expression in indicated MC subsets (n=5 donors); \*, p<0.05, \*\*\*, p<0.001 (t-test).

(H) Intracellular FITC-avidin staining in epithelial MCs (red), CD38<sup>high</sup> subepithelial MCs (orange), and CD38<sup>low</sup> subepithelial MCs (blue).

(I) Quantification of FITC-avidin fluorescence in indicated MC subsets (n=9 donors); \*, p<0.05 (t-test).



**Figure 7: Unpolarized MC proliferation underlies MC expansion in human nasal polyps.**  
**(A)** Schematic approach for Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq) analysis of sorted polyp-derived MCs  
**(B)** Identification of four clusters across 2,902 MCs from 2 donors with expression of the MC1 and MC3 gene signatures (Supplementary table 2) and *MKI67*.  
**(C)** Cell surface expression of CD117 and CD38 within each MC cluster (line denotes median and quartiles); \*\*,  $p < 1 \times 10^{-4}$ ; \*\*\*,  $p < 1 \times 10^{-12}$ ; \*\*\*\*,  $p < 1 \times 10^{-15}$ ; NS, not significant (Mann-Whitney).

- (D)** UMAP plot showing cell surface expression of Itg $\beta$ 7 across nasal polyp MCs.
- (E)** Representative plot of nuclear Ki67 in nasal polyp MCs.
- (F)** Overlay showing Ki67+ MCs (purple) and all MCs (grey) with flow gates defined in Fig. 6A (left). Quantification of Ki67+ MCs by subset (right); \*\*\*,  $p < 0.001$  (t-test).
- (G)** Quantification of Ki67+ MCs in indicated disease endotypes. \*\*\*,  $p < 0.001$ , (t-test).
- (H)** Correlation of MC proliferation (Ki67 staining) and peripheral blood eosinophil counts across polyp patients. Pearson  $R = 0.481$ ,  $p < 0.05$

**Table 1:**  
**Identification of inflammation-associated airway MCT transcripts across datasets.**

Transcripts significantly elevated in *CD38*, *IL17RB* and *GPR183*-enriched MCs ( $p < 0.05$ ) in at least two of the three lung fibrosis scRNA-seq datasets analyzed. Transcripts in bold were significantly elevated in polyp MC3 (MC<sub>T</sub>) relative to other polyp subsets. Blue transcripts were significantly elevated within the CD38-enriched asthma MC cluster analyzed in Fig S6.

Banovich & Kropski	+	+	+	-
Kaminski & Rosas	+	+	-	+
Lafayatis	+	-	+	+
	<i>ACTG1</i>	<i>ABRACL</i>	<i>B4GALT5</i>	<i>AKAP12</i>
	<b><i>CD38</i></b>	<i>ACTR3</i>	<i>BCL2A1</i>	<i>ARHGEF6</i>
	<b><i>CD52</i></b>	<i>CAPG</i>	<i>CALR</i>	<i>CELF2</i>
	<i>CPA3</i>	<i>EEF1G</i>	<i>CAMK1</i>	<i>EEF2</i>
	<i>CXCR4</i>	<i>EIF2A</i>	<i>CD83</i>	<i>FBXO34</i>
	<i>DTNBP1</i>	<i>HOTAIRM1</i>	<i>CDC42</i>	<i>LCP2</i>
	<b><i>EEF1A1</i></b>	<i>LTC4S</i>	<i>CKS2</i>	<i>NEDD9</i>
	<b><i>GPR183</i></b>	<i>MYL12B</i>	<i>CREM</i>	<i>PLXNC1</i>
	<b><i>IL17RB</i></b>	<i>NKG7</i>	<i>DUSP10</i>	<i>PROM1</i>
	<i>LDLRAD4</i>	<b><i>RPL10A</i></b>	<i>DUSP4</i>	<i>RPL28</i>
	<i>LGALS1</i>	<b><i>RPL13A</i></b>	<i>EHD1</i>	<i>RPLP0</i>
	<i>MAFF</i>	<i>RPL15</i>	<i>FOSL2</i>	<i>SLC9A1</i>
	<b><i>NSMCE1</i></b>	<b><i>RPL3</i></b>	<i>GALNT6</i>	
	<i>PFN1</i>	<i>RPL7</i>	<i>GEM</i>	
	<b><i>RGS16</i></b>	<i>RPS2</i>	<i>HES4</i>	
	<b><i>RPL4</i></b>	<i>RPS5</i>	<i>HEY1</i>	
	<b><i>RPSA</i></b>	<b><i>RPS6</i></b>	<i>ICAM3</i>	
	<i>ZC3H12A</i>	<i>RPS9</i>	<i>ID2</i>	
		<i>SVOPL</i>	<i>ISG15</i>	
		<i>TMSB4X</i>	<i>KDM6B</i>	
		<i>TPI1</i>	<i>KPNA2</i>	
		<i>TPSAB1</i>	<i>LMNB1</i>	
		<i>UQCRH</i>	<i>MAT2A</i>	
			<i>MCL1</i>	
			<i>NFATC1</i>	
			<i>NR4A1</i>	
			<i>NR4A2</i>	
			<i>NR4A3</i>	
			<i>NUDT14</i>	
			<i>PHLDA1</i>	
			<i>PLAUR</i>	

			<i>PMEPA1</i>	
			<i>PRKD3</i>	
			<i>PTGS2</i>	
			<i>RAB33A</i>	
			<i>RANBP2</i>	
			<i>SETP9</i>	
			<i>RUNX3</i>	
			<i>SH2D2A</i>	
			<i>SKIL</i>	
			<i>SLC16A3</i>	
			<i>SRSF2</i>	
			<i>TGIF1</i>	
			<i>TNFAIP8</i>	
			<i>TNFRSF9</i>	
			<i>TPM4</i>	
			<i>TPT1</i>	
			<i>ZFAND5</i>	
			<i>ZNF331</i>	

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript